Neoantigen load as a prognostic and predictive marker for stage II/III non-small cell lung cancer in Chinese patients
文献类型：期刊论文
| 作者 | Gong, Lei1,7; He, Ronghui2; Xu, Yanjun1,7; Luo, Taobo3,7; Jin, Kaixiu2; Yuan, Wuzhou4; Zheng, Zengguang5,7; Liu, Lanxuan2; Liang, Zebin2; Li, Ao4 |
| 刊名 | THORACIC CANCER
 |
| 出版日期 | 2021-06-15 |
| ISSN号 | 1759-7706 |
| 关键词 | biomarker neoantigen load NSCLC prognosis whole exome sequencing |
| DOI | 10.1111/1759-7714.14046 |
| 通讯作者 | Zheng, Zhiguo(zhengzg@zjcc.org.cn) ; Li, Hui(11118029@zju.edu.cn) |
| 英文摘要 | Background The prognosis for patients with stage II/III non-small cell lung cancer (NSCLC) is unsatisfactory, even after complete tumor resection and adjuvant chemotherapy. Here, we assessed the prognostic and predictive value of immunogenomic signatures for stage II/III NSCLC in Chinese patients. Methods A total of 91 paired resected stage II/III NSCLC and normal tissues, including 47 squamous cell lung carcinomas (SCC) and 44 lung adenocarcinomas (ADC), were collected and analyzed using whole exome sequencing (WES) to identify immunogenomic signatures for association with clinicopathological variables and disease-free survival (DFS). Results Higher neoantigen load (NAL, >2 neoantigens/Mb) exhibited better DFS for SCC patients (p = 0.021) but not ADC patients. A benefit from adjuvant chemotherapy was correlated with lower NAL (<= 2 neoantigens/Mb) (p = 0.009). However, tumor mutation burden (TMB), mutations of individual gene, oncogene pathways, and antigen presentation machinery genes, and human leukocyte antigen (HLA)-I number and HLA-I loss of heterozygosity (LOH) had no prognostic or predictive value for DFS of SCC or ADC patients. Conclusions NAL is a useful biomarker for lung SCC prognosis and prediction of chemotherapy responses in Chinese patients. The predictive value of NAL for adjuvant immunotherapy should be further explored in patients with resected NSCLC. |
| WOS关键词 | TUMOR ; BURDEN |
| 资助项目 | Natural Science Foundation of Zhejiang Province[LQ21H160004] ; Zhejiang Medical technology program[202143913] |
| WOS研究方向 | Oncology ; Respiratory System |
| 语种 | 英语 |
| 出版者 | WILEY |
| WOS记录号 | WOS:000661389300001 |
| 资助机构 | Natural Science Foundation of Zhejiang Province ; Zhejiang Medical technology program |
| 源URL | [http://ir.hfcas.ac.cn:8080/handle/334002/123772]  |
| 专题 | 中国科学院合肥物质科学研究院 |
| 通讯作者 | Zheng, Zhiguo; Li, Hui |
| 作者单位 | 1.Univ Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp, Dept Med Oncol, Hangzhou 310022, Peoples R China 2.Hangzhou YITU Healthcare Technol Co Ltd, Hangzhou, Peoples R China 3.Univ Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp, Dept Thorac Surg, Hangzhou, Peoples R China 4.Mingma Technol Co Ltd, Shanghai, Peoples R China 5.Univ Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp, Dept Pathol, Hangzhou, Peoples R China 6.Univ Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp, Zhejiang Canc Res Inst, Hangzhou 310022, Peoples R China 7.Chinese Acad Sci, Inst Basic Med & Canc IBMC, Hangzhou 310022, Peoples R China |
| 推荐引用方式 GB/T 7714 | Gong, Lei,He, Ronghui,Xu, Yanjun,et al. Neoantigen load as a prognostic and predictive marker for stage II/III non-small cell lung cancer in Chinese patients[J]. THORACIC CANCER,2021. |
| APA | Gong, Lei.,He, Ronghui.,Xu, Yanjun.,Luo, Taobo.,Jin, Kaixiu.,...&Li, Hui.(2021).Neoantigen load as a prognostic and predictive marker for stage II/III non-small cell lung cancer in Chinese patients.THORACIC CANCER. |
| MLA | Gong, Lei,et al."Neoantigen load as a prognostic and predictive marker for stage II/III non-small cell lung cancer in Chinese patients".THORACIC CANCER (2021). |
入库方式： OAI收割
来源：合肥物质科学研究院
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。